Tenascin as a Prognostic Marker in Colorectal Cancer
Author Information
Author(s): U Kressner, G Lindmark, B Tomasini-Johansson, R Bergstrom, B Gerdin, L Pahlman, B Glimelius
Primary Institution: University Hospital, University of Uppsala
Hypothesis
The study investigates the association between tenascin staining patterns and survival in colorectal cancer patients.
Conclusion
Diffuse stromal fibrillar staining of tenascin is associated with shorter survival in colorectal cancer patients compared to subglandular staining.
Supporting Evidence
- 54% of tumors showed diffuse stromal fibrillar staining.
- Patients with diffuse staining had a significantly shorter survival time.
- Dukes' stage and age were independent prognostic factors.
Takeaway
This study found that a specific protein called tenascin can help predict how long patients with colorectal cancer might live after treatment.
Methodology
Immunohistochemical staining was performed on cryosections of colorectal adenocarcinomas to evaluate tenascin expression in relation to tumor stage, differentiation, and survival.
Limitations
The additional prognostic value of tenascin remains to be established in further analyses after adjusting for age and Dukes' stage.
Participant Demographics
72 men and 97 women, ages ranging from 40 to 92 years, with a median age of 71.
Statistical Information
P-Value
0.06
Confidence Interval
0.98-2.99
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website